Company intelligence / Profile preview

PGxAI

Palo Alto, California, United States

Ownership: Private
Development stage: Other

Overview

PGxAI's AI-powered platform delivers pharmacogenomic recommendations covering 730+ drugs and 40+ key genes, deployed in clinical reporting and real-world studies, though clinical trial efficacy summaries as for therapies do not apply.

Therapeutic areas: Other
Modalities: Not directly applicable (PGxAI provides AI-powered pharmacogenomics insights and decision support rather than therapeutics)
Industry: Molecular Diagnostics

Partnerships

Sequencing.com (integration and report delivery)InterSystems (data platform partnership)Dynamic DNA (diagnostic lab partnership)UBC (University of British Columbia, academic collaboration)NVIDIA (GPU/AI development)Google (cloud infrastructure/compute)Microsoft (cloud infrastructure/compute)

Beyond the preview

Go deeper on PGxAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGxAI.

Explore the full profile